We are live on
!
Find out more
AFA
Arlington Financial Advisors Portfolio holdings
AUM
$787M
1-Year Est. Return
22.93%
This Fund
S&P 500
This Quarter
Est. Return
+22.62%
1 Year Est. Return
+22.93%
3 Year Est. Return
+60.65%
5 Year Est. Return
+68.7%
10 Year Est. Return
–
AUM
$237M
AUM Growth
+$41.9M
(+21%)
Cap. Flow
+$2.88M
Cap. Flow
% of AUM
1.22%
Top 10 Holdings %
Top 10 Hldgs %
58.82%
Holding
62
New
5
Increased
32
Reduced
13
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.62M |
| 2 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$869K |
| 3 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$687K |
| 4 |
PIMCO RAFI ESG US ETF
RAFE
|
+$425K |
| 5 |
iShares MSCI KLD 400 Social ETF
DSI
|
+$413K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$1.68M |
| 2 |
Chevron
CVX
|
+$742K |
| 3 |
Apple
AAPL
|
+$318K |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$245K |
| 5 |
Johnson & Johnson
JNJ
|
+$212K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 8.18% |
| 2 | Financials | 7.69% |
| 3 | Technology | 7.24% |
| 4 | Healthcare | 5.55% |
| 5 | Communication Services | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Gilead Sciences
GILD
$162B
| $436K | 0.18% |
7,489
-27,922
| -79% | -$1.68M |
|
52
Allstate
ALL
$68B
| $364K | 0.15% |
3,310
| – | – |
|
|
XYZ
53
Block Inc
XYZ
$48.4B
| $305K | 0.13% |
1,400
| – | – |
|
54
Editas Medicine
EDIT
$396M
| $294K | 0.12% |
+4,200
| New | +$173K |
|
55
Truist Financial
TFC
$63.3B
| $280K | 0.12% |
5,844
| – | – |
|
56
Appian
APPN
$1.98B
| $259K | 0.11% |
+1,600
| New | +$179K |
|
57
Atlassian
TEAM
$25.6B
| $246K | 0.1% |
+1,050
| New | +$222K |
|
58
Adobe
ADBE
$99.5B
| $227K | 0.1% |
453
-27
| -6% | -$13K |
|
59
GE Aerospace
GE
$374B
| $227K | 0.1% |
4,214
| – | – |
|
60
Kimberly-Clark
KMB
$36.3B
| $216K | 0.09% |
1,600
| – | – |
|
61
Lowe's Companies
LOW
$117B
| – | – |
-1,234
| Closed | -$205K |
|
|
62
Vertex Pharmaceuticals
VRTX
$121B
| – | – |
-900
| Closed | -$245K |
|
Similar funds
SBCM
SWIG
GCM
NEAM
VH
MTWSIF
JSL
LSPW
Arlington Financial Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, Arlington Financial Advisors held 62 positions worth $237M, up 21% from $195M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Arlington Financial Advisors's Q4 2020 filing shows 5 new, 32 increased, 13 reduced and 2 closed positions. Its largest new stake was Bristol-Myers Squibb: 26,354 shares worth $1.64M. The largest sale was Gilead Sciences, an estimated $1.68M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 8.2% of assets, up from 8.1% a quarter earlier, followed by Financials and Technology.
- Arlington Financial Advisors's largest Q4 2020 buy was Bristol-Myers Squibb: 26,354 shares worth $1.64M.
- Arlington Financial Advisors added most to Schwab Fundamental US Large Company Index ETF in Q4 2020, an estimated $869K increase.
- Arlington Financial Advisors's biggest Q4 2020 reduction was Gilead Sciences, cutting an estimated $1.68M.
- Arlington Financial Advisors fully exited Vertex Pharmaceuticals in Q4 2020, selling an estimated $245K.
- Arlington Financial Advisors's ten largest holdings make up 59% of its $237M portfolio in Q4 2020.
- Arlington Financial Advisors opened 5 new positions and closed 2 in Q4 2020.
- Arlington Financial Advisors's portfolio value rose 21% quarter-over-quarter to $237M.
Based on Arlington Financial Advisors's 13F filing for Q4 2020, filed 29 Jan 2021.